<DOC>
	<DOCNO>NCT03042520</DOCNO>
	<brief_summary>Primary Objective : To evaluate long-term outcome include liver relate morbidity , mortality hepatocellular carcinoma ( HCC ) development compare historical control interferon ( IFN ) -based treatment . Secondary Objective : 1 . To access liver fibrosis progression/regression CHC patient sofosbuvir-based treatment . 2 . To investigate long-term outcome extrahepatic manifestation sofosbuvir-based treat cohort compare pretreatment status .</brief_summary>
	<brief_title>Long-term Outcomes Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment</brief_title>
	<detailed_description>Primary Endpoint : To evaluate long-term event-free effect sofosbuvir-based therapy , term free major liver event ( include HCC , decompensation ascites , variceal bleeding , hepatic encephalopathy , liver-related mortality ) CHC patient . Secondary Endpoints : 1 . To evaluate hepatic fibrosis progression regression CHC patient sofosbuvir-based therapy . 2 . To evaluate durability sustain viral response ( SVR ) patient achieve SVR sofosbuvir-based therapy . 3 . To evaluate long-term effect sofosbuvir-based therapy extra-hepatic manifestation cohort . The item include mixed cryoglobulinemia , chronic kidney disease , insulin resistance , diabetic status , cardiovascular event dyslipidemia . 4 . To evaluate long-term effect sofosbuvir-based therapy quality life cohort . Study Design Prospective , longitudinal observational study Study procedure A total 200 patient receive sofosbuvir base direct antiviral agent ( DAAs ) parent study include follow 5 year . Their serological , image study disease status description prospectively document present long term effect sofosbuvir-based therapy . The presentation illness specify : 1 . Main hepatic complication liver fibrosis , hepatic malignancy , liver decompensation ascites , hepatic encephalopathy variceal bleeding , liver-related mortality . 2 . Life quality , extrahepatic symptom cryoglobulinemia , diabetes mellitus , insulin resistance , lipid profile , renal insufficiency non-liver morbidity malignancy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Cryoglobulinemia</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Main inclusion criterion : For Sofosbuvirbased therapy observational group : Patients ≥ 20 year ever participate parent study , GSUS3370131 ( NCT02021656 ) GSUS3340115 ( NCT02021643 ) Patients receive least one dose sofosbuvirbased therapy parent study . Who IFNbased therapy historical control , match sex , age , level liver fibrosis virological response : Patients ≥ 20 year receive pegylated interferon plus ribavirin therapy match sex , age , level liver fibrosis virological response Patients ever participate study collect historical control . Main exclusion criterion : Patients qualify main inclusion criterion exclude . For Sofosbuvirbased therapy observational group : Patients &lt; 20 year Patients unwilling participate current study Patients never participate parent study , GSUS3370131 ( NCT02021656 ) GSUS3340115 ( NCT02021643 ) Patients never receive least one dose sofosbuvirbased therapy parent study . Who IFNbased therapy historical control : Patients &lt; 20 year Patients unwilling participate current study Patients never receive pegylated interferon plus ribavirin therapy Patients participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>